• Trending
  • Latest
    Sign in Sign up
    • Log In
    • Register
    • Home
    • Discover
    • Experts
    • Home
    • Discover
    • Experts
    • Learning Lab
    • Home
    • Discover
    • Experts
    • Learning Lab
    • Mashup Score: 0
      Zyprexa Added to Standard Antiemetics Reduces Nausea, Vomiting in Radiation - 57 minute(s) ago

      Adding Zyprexa to ondansetron cut nausea and vomiting safely in abdominal/pelvic radiation with low-emetogenic capecitabine.

      Source: www.curetoday.com
      Categories: General Medicine News, Nursing
      Tweet Tweets with this article
      • Profile photo of 	cure_today
        cure_today

        Adding Zyprexa to ondansetron cut nausea and vomiting safely in abdominal/pelvic radiation with low-emetogenic capecitabine. @ASCO #ASCO25 #Oncology #MedEd #MedTwitter Get more insights on the news here: https://t.co/Vzwff76kAo https://t.co/t7d5fVQmLn

    • Mashup Score: 0
      FDA Approves Perioperative Keytruda for Locally Advanced Head and Neck Cancer - 2 hour(s) ago

      Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free survival versus standard care.

      Source: www.curetoday.com
      Categories: General Medicine News, Nursing
      Tweet Tweets with this article
      • Profile photo of 	cure_today
        cure_today

        Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free survival versus standard care. @US_FDA #HeadandNeckCancer https://t.co/xztx1i9T9i https://t.co/eZliqQrm7g

    • Mashup Score: 0
      Columvi Combo Enhances Survival Outcomes in R/R Lymphoma Subgroup - 2 hour(s) ago

      Columvi plus chemo had enhanced survival outcomes vs Rituxan plus chemo in patients with relapsed/refractory diffuse large B-cell lymphoma.

      Source: www.curetoday.com
      Categories: General Medicine News, Nursing
      Tweet Tweets with this article
      • Profile photo of 	cure_today
        cure_today

        Columvi plus chemo had enhanced survival outcomes vs Rituxan plus chemo in patients with relapsed/refractory diffuse large B-cell lymphoma. @JSALymphomaDoc @harvardmed @ASCO #ASCO25 #Lymphoma https://t.co/LQ25B7WhLf

    • Mashup Score: 0
      Beyond Treatment: How Support Groups Helped Me Embrace My New Normal - 4 hour(s) ago

      Joining support groups after cancer treatment helped me heal emotionally, connect with others who understood and embrace a new, meaningful normal.

      Source: www.curetoday.com
      Categories: General Medicine News, Nursing
      Tweet Tweets with this article
      • Profile photo of 	cure_today
        cure_today

        Beyond Treatment: How Support Groups Helped Me Embrace My New Normal #Oncology https://t.co/R9zygU2U5p

    • Mashup Score: 1
      Bringing Light to More Personalized Medicine in Lung Cancer After ASCO 2025 - 5 hour(s) ago

      Expert oncologists Dr. Joshua K. Sabari and Dr. Eric K. Singhi break down key updates and takeaways in lung cancer treatment following ASCO 2025.

      Source: www.curetoday.com
      Categories: General Medicine News, Nursing
      Tweet Tweets with this article
      • Profile photo of 	cure_today
        cure_today

        Bringing Light to More Personalized Medicine in Lung Cancer After ASCO 2025 @JSabari @lungoncdoc @MDAndersonNews @Perlmutter_CC @ASCO #ASCO25 #LungCancer https://t.co/gLqmOabxSh

    • Mashup Score: 0
      How Love Helped Me Overcome my Cancer Diagnosis - 6 hour(s) ago

      Facing two life-threatening diagnoses, I overcame fear of self-injections by leaning on love, encouragement and determination to save my life.

      Source: www.curetoday.com
      Categories: General Medicine News, Nursing
      Tweet Tweets with this article
      • Profile photo of 	cure_today
        cure_today

        How Love Helped Me Overcome my Cancer Diagnosis #CancerDiagnosis https://t.co/DSDVM5qswj

    • Mashup Score: 2
      FDA Approves UGN-102 For Some With Bladder Cancer - 7 hour(s) ago

      The FDA has granted approval to UGN-102 for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.

      Source: www.curetoday.com
      Categories: General Medicine News, Nursing
      Tweet Tweets with this article
      • Profile photo of 	cure_today
        cure_today

        🚨 BREAKING: The U.S. FDA has approved UGN-102 for some patients with bladder cancer. #bladdercancer https://t.co/wSXBzCzZrF

    • Mashup Score: 8
      What Patients With Genitourinary Cancers Need to Know After ASCO 2025 - 9 hour(s) ago

      Dr. Joshua K. Sabari and Dr. Daniel V. Araujo provide expert insights into genitourinary cancer updates from ASCO 2025.

      Source: www.curetoday.com
      Categories: General Medicine News, Nursing
      Tweet Tweets with this article
      • Profile photo of 	cure_today
        cure_today

        What Patients With Genitourinary Cancers Need to Know After ASCO 2025 @JSabari @DVAraujoMD @UFHealthCancer @Perlmutter_CC @ASCO #ASCO25 https://t.co/ywbkB0oZCT

    • Mashup Score: 1
      FDA Approves Brukinsa Tablet For Various Blood Cancers - 10 hour(s) ago

      FDA approves new Brukinsa tablet for five blood cancers, offering simpler dosing with the same safety and effectiveness as capsules.

      Source: www.curetoday.com
      Categories: General Medicine News, Nursing
      Tweet Tweets with this article
      • Profile photo of 	cure_today
        cure_today

        FDA Approves Brukinsa Tablet For Various Blood Cancers @US_FDA #Oncology #MedEd #MedTwitter https://t.co/SapUo5x2Qu

    • Mashup Score: 4
      A New Therapeutic Approach May Make Waves in Kidney Cancer Treatment - 11 hour(s) ago

      Dr. Michael Serzan provides expert takeaways on treatment updates for patients with early-stage kidney cancer following the 2025 ASCO Meeting.

      Source: www.curetoday.com
      Categories: General Medicine News, Nursing
      Tweet Tweets with this article
      • Profile photo of 	cure_today
        cure_today

        A New Therapeutic Approach May Make Waves in Kidney Cancer Treatment @MikeSerzanMD @DanaFarber @DanaFarberNews #Oncology #MedEd #KidneyCancer https://t.co/UMStcUFj1I

    Load More
    ASCO 2025

    Advertisement

    Advertisement

    MashupMD
    © 2025 - Mashup Media LLC
    • Terms of Use
    • Privacy Policy
    • Cookie Settings